A Service of Decision Resources
Discovery and Innovation: Technologies, Strategies, and Dealmaking
Barbara M. Bolten, M.S., M.B.A., Senior Program Manager
Inﬂuenza Vaccine Manufacturing: Can New
Technologies Open the Production Bottleneck?
Barbara M. Bolten, M.S., M.B.A.
With the threat of swine ﬂu in 2009 came vaccine shortages, long lines at distribution centers, and frustrated
consumers. New technologies for manufacturing ﬂu vaccines could increase the speed and efﬁciency of produc-
ing vaccines and help to avoid these problems. The European Commission’s approval of Novartis’s Optaﬂu in
2007 was a signiﬁcant step forward for cell-based production methods, and many competitors are jumping into
the race to develop the next generation of inﬂuenza vaccines.
Questions Answered in This Report:
• Pandemic inﬂuenza threats and outbreaks have had a dramatic impact on the overall inﬂuenza vaccine mar-
ket. What fundamental changes to the dynamics of the marketplace occurred as a result of the H5N1
avian inﬂuenza threat? How did governments respond to the 2009 A/H1N1 pandemic? How did this
outbreak affect vaccine manufacturers?
• The manufacture of inﬂuenza vaccines is based on antiquated methods initially developed in the 1940s.
What new methods are being implemented to increase the efﬁciency and speed of manufacturing
inﬂuenza vaccine? Which companies are leading this trend?
• The drive to create new manufacturing methods is prompting innovative development efforts throughout
the industry. What cutting-edge technologies are most advanced in development? Which companies
are investing in and developing these technologies?
• Collaboration among pharmaceutical companies and biotech companies as well as government support and
participation are key to accelerating the development of new vaccine manufacturing technologies. Which
companies are involved in inﬂuenza-vaccine-related dealmaking? How is the U.S. government pro-
moting and supporting inﬂuenza vaccine development?
Decision Resources • 260 Charles Street, Waltham, Massachusetts 02453
• Tel +1.781.296.2500 • Fax +1.781.296.2550 • www.decisionresources.com •
For questions regarding this report, contact: Barbara Bolten Tel +1.781.296.2579 • E-mail: firstname.lastname@example.org
For questions regarding consulting, contact: Jim McDermott Tel +1.781.296.2522 • E-mail email@example.com
For questions regarding sales, service, and technical support, contact:
United States: Tel +1.781.296.2662 • Fax +1.781.296.2550 • Europe: Tel +32.2.357.06.16 • Fax +32.2.351.2347
Japan: Tel +81.3.5401.2615 • Fax +81.3.5401.2617
• Inﬂuenza disease and prevention: Occurrence and impact of seasonal and pandemic inﬂuenza
infections, emerging pandemics, the threat and impact of the H5N1 avian ﬂu virus.
• The 2009 A/H1N1 pandemic: Threat, spread, and results of 2009 A/H1N1 infections, government
response, vaccine approvals.
• Impact of 2009 A/H1N1: Vaccine shortages and surpluses, ﬁnancial impact on vaccine manufac-
turers, Decision Resources’ Pharmaview historical sales data and forecast for inﬂuenza vaccines.
• Egg-based manufacturing methods: Strain identiﬁcation, seed production, production methods,
• Mammalian-cell-based methods: Production processes, cell lines, Novartis, Baxter International,
Solvay Pharmaceuticals, Crucell.
• Emerging technologies: Baculovirus production systems, recombinant antigens, virus-like
particles, toll-like-receptor-based platform, universal vaccines, DNA vaccines, Protein Sciences,
Novavax, VaxInnate, Dynavax, Vical.
• Outlook for inﬂuenza vaccine manufacturing: Impact of drawbacks on current methods, promo-
tion and development of cell-based methods, adjuvants, emerging markets.
Mentioned in This Report:
• Abbott Laboratories • ID Biomedical • Select Vaccines
• Antigen Express • Immune Targeting Systems • ShanH
• AstraZeneca • Inovio Biomedical • Shantha Biotechnics
• Avimex Laboratories • Intercell • Shenzen Neptunus Interlong
• Baxter International • Isconova Biotechnique
• Bharat Biotech • Johnson & Johnson • Sinovac Biotech
• Biological E • Juvaris BioTherapeutics • Solvay Biologicals
• Cadila Pharmaceuticals • Lentigen • Solvay Pharmaceuticals
• Chiron • MedImmune (AstraZeneca • TechnoVax
• CPL Biologicals subsidiary) • Theraclone Sciences
• Crucell • Merck & Co. • UMN Pharma
• CSL Biotherapies • Merieux Alliance • Vaxart
• Dynavax Technologies • Mucosis • Vaxine
• DynPort Vaccine Company • NanoBio • VaxInnate
• Eurocine Vaccines • Neugenesis • Vical
• FluGen • Novartis • ViraBiotech
• Folia Biotech • Novavax • Vivaldi Biosciences
• GE Healthcare • PaxVax • Vivalis
• Generex Biotechnology • Protein Sciences • Xcellerex
• GlaxoSmithKline • Roche • Zhejiang Tianyuan
• GlobeImmune • Sanoﬁ Pasteur BioPharmaceuticals
• iBioPharma • Sanoﬁ-Aventis
Key Terms for This Report:
A/H1N1, Baculovirus, Cell-based, Celvapan, Crucell, Dynavax, Inﬂuenza, Novavax, Optaﬂu,
Pandemic, Protein Sciences, Swine ﬂu, Universal vaccine, Vaccine, VaxInnate
Decision Resources 3-2
Look for relevant insight within these Spectrum series and
related Spectrum reports:
Discovery and Innovation: Technologies, Strategies, and Dealmaking identiﬁes and
evaluates cutting-edge technologies for drug discovery and design and examines the
impact that new technologies will have on the pharmaceutical R&D process. Our analyses
identify the innovators who are developing the hottest technologies and help you to make
important business development and licensing decisions to capitalize on these game-
Select titles from Discovery and Innovation: Technologies, Strategies, and
• Investment and Dealmaking Trends in Biotechnology
• Can Innovative Technology Platforms Improve R&D Productivity?
• Insights into Platform Technology and Early-Stage Pipeline Mergers and Acquisitions
• New Strategies in Academic-Industry Collaborations
• Strategies for Building Early-Stage Pipelines Through External Sources
• Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?
Therapeutic Markets – Opportunities and Pipeline Analysis provides comprehensive
review and analysis of a wide range of drug classes and therapeutic indications, including
major disease states, orphan diseases, and niche markets, with an emphasis on key
established and emerging players. The insights contained in these reports will help you
understand speciﬁc marketplaces and shape your strategy to maximize the commercial
potential of your pipeline.
Select titles from Therapeutic Markets – Opportunities and Dynamics:
• SPECIAL REPORT: Opportunities and Market Outlook in Respiratory Syncytial Virus
• SPECIAL REPORT: Gardasil Versus Cervarix in the Human Papillomavirus Market
• SPECIAL REPORT: The Pandemic Paradigm—Balancing Commercial Opportunities
with Public Health Concerns in the Face of A/H1N1 2009
• Emerging Pharmaceutical Blockbusters: 2010’s Billion-Dollar Babies
Strategic Overview of the Antivirals Marketplace
Sales of Roche’s Tamiﬂu increased 435% in 2009 as a result of the H1N1 pandemic,
highlighting the revenue potential of the marketplace but also the vagaries that make
this arena a challenging one. What issues are companies active in this marketplace
confronting? What strategies are they employing to compete successfully? What is the
status of R&D? This comprehensive strategic overview -- which incorporates the insights
of 100 board-certiﬁed U.S. infectious disease specialists -- explores a range of issues
relevant to competitors: early-stage R&D targets and approaches; clinical pipelines by
company, target, phase, and more; the role of diagnostics in drug development and
deployment; dealmaking trends; leading companies; and the pricing and reimbursement
environment, including the role of generics.
Decision Resources 3-3